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E-mail address: mutsugi@med.gunma-u.ac.jp (M. UTransforming growth factor-b (TGF-b) plays a pivotal role in the ﬁbrogenic action involved in the
induction of connective tissue growth factor (CTGF), extracellular matrix and ﬁbroblast transforma-
tion. Smad3 mediates TGF-b signaling related to the ﬁbrotic response. In human lung ﬁbroblasts or
bronchial smooth muscle cells, we demonstrated that an increase in the intracellular glutathione
level suppressed TGF-b1-induced phosphorylation of Smad3, while inhibiting TGF-b1-induced
expressions of CTGF, collagen type1, ﬁbronectin and transformation into myoﬁbroblasts, which
are characterized by the expression of a-smooth muscle actin. These data indicate that the intracel-
lular glutathione redox status regulates TGF-b-induced ﬁbrogenic effects through Smad3 activation.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Transforming growth factor-b (TGF-b) plays a pivotal role in ﬁ-
brotic diseases [1,2] such as liver cirrhosis, renal ﬁbrosis, idiopathic
lung ﬁbrosis and airway remodeling in asthma [3]. TGF-b promotes
the production of connective tissue growth factor (CTGF) [4] and
extracellular matrix (ECM) [5] which is mainly represented by col-
lagen type1 and ﬁbronectin [6], and it also transforms ﬁbroblasts
into myoﬁbroblasts which are characterized by a-smooth muscle
actin (a-SMA) expression [7]. CTGF is speciﬁcally induced by
TGF-b [4] and it plays a pivotal role in many ﬁbrotic diseases
through mediating TGF-b-induced ﬁbroproliferative effects [5,8].
TGF-b has been shown to enhance ECM synthesis in combination
with CTGF, suggesting that the induction of CTGF expression is re-
lated to the development of ﬁbrosis by TGF-b [6] and that CTGFchemical Societies. Published by E
C, bronchial smooth muscle
wth factor; DEX, dexameth-
ylcystein ethyl ester; GSH,
L-1, human lung ﬁbroblasts;
ressed and-secreted chemo-
tsugi).acts as a TGF-b cofactor for the promotion of ﬁbrosis [8]. In addi-
tion, transformed myoﬁbroblasts can contrast more strongly and
produce more ECM than ﬁbroblasts [3,5], thus resulting in pro-
gressing ﬁbrosis.
Smad protein mediates TGF-b signaling from the cell membrane
to nucleus [9]. Smad3, as well as Smad2, is phosphorylated by acti-
vated TGF-b receptor, then after forming a complex with Smad4, it
translocates to the nucleus, and regulates the transcription of var-
ious TGF-b-responsive gene. Many reports have described that
Smad3 mediates TGF-b-induced ﬁbrogenic action involved in
ECM deposition and myoﬁbroblasts differentiation [10]. Smad3
knockout mice are protected against progressive pulmonary ﬁbro-
sis induced by the transient overexpression of active TGF-b1 in
contrast to wild-type mice [11]. An overexpression Smad3 in hu-
man lung ﬁbroblasts markedly increased TGF-b1-induced a-SMA
promoter activity [12], and a deletion of Smad3 results in a reduc-
tion in the number of peribronchial myoﬁbroblasts in the airway
remodeling of asthma model mice [13]. Furthermore, the promoter
region of CTGF has the Smad binding site which is essential for
TGF-b-induced CTGF expression [14]. These reports indicate that
Smad3 mediates TGF-b-induced ﬁbrogenic action involved in the
expression of CTGF or ECM gene and transformation into
myoﬁbroblasts.lsevier B.V. All rights reserved.
Fig. 1. Effect of c-GCE on the intracellular GSH level. After incubating HFL-1 cells
(A) and BSMC (B) with c-GCE for 4 h, the GSH level was determined using an
enzyme assay. Values represent means ± S.E.M. of four (A) and ﬁve (B) experiments
*P < 0.05 compared with c-GCE untreated cells.
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and it is a major intracellular redox buffer [15]. Glutathione redox
has been reported to not only have an anti-oxidative action but
also regulate many kinds of cellular biological functions. We have
previously reported that the intracellular glutathione redox status
in antigen presenting cells regulates the Th1/Th2 balance through
the production of interleukin-12 [16,17]. However, the role of glu-
tathione redox in the pathogenesis of ﬁbrotic lung disease has not
yet been determined. Therefore, the present study was designed to
investigate the effect of glutathione redox on TGF-b-induced ﬁbro-
genic action in human lung ﬁbroblasts and airway smooth muscle
cells using c-glutamylcystein ethyl ester (c-GCE) which is a pre-
cursor of reduced glutathione (GSH) biosynthesis. In addition, the
effects of c-GCE were compared with those of dexamethasone
(DEX), which is a synthetic corticosteroid and is often used for
the treatment of ﬁbrotic diseases.2. Materials and methods
2.1. Reagents
Recombinant human TGF-b1 was obtained from R&D Systems
(Minneapolis, MN). c-GCE is a hydrophilic chemical compound ofFig. 2. Effect of c-GCE on TGF-b1-induced Smad3 activation. HFL-1 cells (A) and BSMC
40 min. Phosphorylated forms of Smad3 were determined using Western blotting. The co
and indicate the amount of enzyme that was precipitated. Levels of Smad3 phosphoryla
expressed as ratio (%) of control value. Values represent means ± S.E.M. of three (C) or fdiamino-acid that is the precursor of GSH; it was kindly donated
by Teijin Pharma Limited (Tokyo, Japan). DEX was purchased from
Sigma (St. Louis, MO).
2.2. Cell culture
Human lung ﬁbroblasts (HFL-1) were purchased from the
American Type Culture Collection (Rockville, MD) and cultured as
previously described [18]. Human bronchial smooth muscle cells
(BSMC) were purchased from Clonetics (San Diego, CA) and cul-
tured as previously described [19]. Before reaching conﬂuence,
the cells were washed and cultured overnight in fresh medium
without fetal bovine serum. After pretreatment with or without
c-GCE or DEX, the cells were stimulated with 1 ng/ml TGF-b.
2.3. Measurement of intracellular GSH concentrations
HFL-1 cells and BSMC cultured subconﬂuently in six well plates
were treated with 0–10 mM of c-GCE for each time period. The
cells in each well were thawed in 200 ll lysis buffer (0.1% triton-
X, 0.1 M sodium phosphate, 5 mM EDTA, pH 7.5) and homoge-
nized. The lysates were acidiﬁed with 30 ll of 0.1 N HCl, and pro-
tein was precipitated with 30 ll of 50% sulfosalicylic acid. The GSH
levels were determined as previously described [16].
2.4. Western blotting
Western blotting was performed as previously described [20].
The primary antibody selectively recognizing phosphorylated form
of Smad3 (anti-phospho-Smad3, Ser423/425) and phosphorylation
state-independent anti-Smad3 antibody to determine the amounts
of precipitated Smad3 were obtained from Cell Signaling Technol-
ogy (Beverly, MA).
2.5. Real-time PCR analysis
The total RNA from HFL-1 or BSMC cells was treated by DNase
using an RNeasy Mini Kit and RNase-Free DNase Set (QIAGEN,
Valencia, CA), and converted to cDNA using a High-Capacity cDNA
Archive kit (Applied Biosystems, Foster, CA). The transcription(B) were treated with or without c-GCE for 4 h before stimulation by TGF-b1 for
rresponding bottom panels show the Western blots using antibodies to total Smad3,
tion in HFL-1 cells (C) and BSMC (D) were quantiﬁed by densitometry. Results are
our (D) experiments *P < 0.05 compared with c-GCE untreated cells.
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were detected using real-time PCR (7500 Real-Time PCR System;
PE Applied Biosystems) with the TaqMan Universal PCR Master
Mix (PE Applied Biosystems). The primers and the probes of the
target genes were TaqMan Assay-on-Demand Gene Expression As-
says (PE Applied Biosystems): CTGF (Hs00170014_m1), a-SMA
(Hs00426835_g1), collagen type1 (Hs01028956_m1), ﬁbronectin
(Hs01565277_m1) and, as a control, glyceraldehyde-3-phosphate
dehydrogenase (Hs99999905_m1). The threshold cycle (CT) was
recorded for each sample to calculate the relative expression using
DCT method.
2.6. Statistical analysis
Data were compared using either Student’s t-test or one-way
ANOVA. A P value below 0.05 was considered statistically signiﬁ-
cant. Furthermore if statistical signiﬁcance was reached in the AN-
OVA analysis, post hoc test using Bonferroni/Dunn test was
performed and a P value below 0.05/m (in which m is the number
of comparisons) was considered to be statistically signiﬁcant.3. Results and discussion
3.1. c-GCE increased intracellular GSH levels
The effect of c-GCE, the precursor of GSH, on intracellular GSH
content was determined. c-GCE can pass through the biomem-
brane [21], thus subsequently increasing the intracellular GSH le-
vel. Treatment with c-GCE for 4 h signiﬁcantly increasedFig. 3. The time course of c-GCE treatment on intracellular GSH levels and TGF-b1-ind
(10 mM) for 4 or 16 h. (A) Intracellular GSH levels were determined using an enzyme ass
total Smad3 were determined using Western blotting. (B and D) BSMC were treated with
activity after stimulation by TGF-b1 (D) were determined as described in legend A and C,
compared with c-GCE untreated cells. Levels of Smad3 phosphorylation in HFL-1 cells (E
four (E) or three (F) experiments *P < 0.05 compared with c-GCE untreated cells. N.S.; nintracellular GSH levels in HFL-1 cells (Fig. 1A, P < 0.05) and BSMC
(Fig. 1B, P < 0.05). In both cell types, the maximal intracellular GSH
concentration occurred 4 h after adding c-GCE. In BSMC, there was
no signiﬁcant difference in the intracellular GSH levels between 5
and 10 mM treatment with c-GCE (data not shown).
3.2. c-GCE suppressed TGF-b1-induced Smad3 phosphorylation
Smad3 is thought to be critical signaling molecule in the ﬁbro-
genic effects induced by TGF-b. Therefore, the effect of c-GCE on
TGF-b-induced Smad3 phosphorylation was assessed. HFL-1 cells
were pretreated with c-GCE for 4 h before the stimulation of
TGF-b for 40 min. In contrast to a recent study that GSH did not af-
fect Smad3 phosphorylation in murine embryonic ﬁbroblasts [22],
TGF-b1-induced Smad3 phosphorylation was suppressed by c-GCE
pretreatment in a dose-dependent manner (Fig. 2A) in HFL-1 cells.
A densitometric analysis showed that both 5 and 10 mM c-GCE
signiﬁcantly inhibited TGF-b1-induced Smad3 phosphorylation
(Fig. 2C). Similarly, in the BSMC, TGF-b1-induced Smad3 phosphor-
ylation was suppressed by pretreatment of 5 mM c-GCE (Fig. 2B),
and a densitometric analysis demonstrated 5 mM c-GCE to signif-
icantly inhibit TGF-b1-induced Smad3 phosphorylation (Fig. 2D).
These results suggest that an increased intracellular GSH level
can attenuate TGF-b1-induced Smad3 activation.
3.3. The effect of c-GCE on TGF-b1-induced Smad3 activation is
dependent on the intracellular GSH level
To further investigate the relationship between the intracellu-
lar GSH level and TGF-b-induced Smad3 activation, the timeuced Smad3 activation. (A and C) HFL-1 cells were treated with or without c-GCE
ay. (C) After stimulation by TGF-b1 for 40 min, phosphorylated forms of Smad3 and
or without c-GCE (5 mM) for 4 or 36 h. The intracellular GSH level (B) and Smad3
respectively. Values represent means ± S.E.M. of four (A and B) experiments *P < 0.05
) and BSMC (F) were quantiﬁed by densitometry. Values represent means ± S.E.M. of
o signiﬁcant difference.
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on TGF-b1-induced Smad3 activation was assessed. In HFL-1
cells, the intracellular GSH level was signiﬁcantly increased at
4 h; then, 16 h after adding c-GCE, the intracellular GSH level re-
turned to near basal levels (Fig. 3A). The TGF-b1-induced Smad3
phosphorylation was inhibited by c-GCE pretreatment for 4 h as
the results in Fig. 2, but c-GCE had no inhibitory effect after 16 h
of pretreatment (Fig. 3C). Similarly, in BSMC, c-GCE treatment for
36 h restored both the intracellular GSH level and TGF-b1-in-
duced Smad3 phosphorylation to the levels that were seen in
cells without c-GCE treatment (Fig. 3B and D). A densitometric
analysis showed a signiﬁcant difference in the levels of Smad3
phosphorylation between no treatment and treatment groups
for 4 h with c-GCE in both cells, while no signiﬁcant difference
was observed between no treatment and treatment groups for
16 h (HFL-1) or 36 h (BSMC) with c-GCE (Fig. 3E and F). These
ﬁndings indicate that the change of the intracellular GSH level,
speciﬁcally glutathione redox status, is closely associated with
the levels of TGF-b1-induced Smad3 phosphorylation. In addition,
the recovery of Smad3 activation after c-GCE treatment in the
current study suggested that c-GCE did not have any harmful
effect on these cells.Fig. 4. Effects of c-GCE on TGF-b1-induced CTGF, collagen type1, ﬁbronectin and a-SMA
GCE for 4 h and then were stimulated by TGF-b1 for 8 h (A) or 12 h (B) or 24 h (C, D and
type1 (C), ﬁbronectin (D) or a-SMA (E) was evaluated using a real-time PCR analysis. Th
stimulated cells untreated with c-GCE. Values represent means ± S.E.M. of ﬁve (A, C, D a3.4. c-GCE suppressed TGF-b1-induced CTGF, collagen type1 and
ﬁbronectin expression, and transformation of ﬁbroblasts into
myoﬁbroblasts
CTGF and ECM expressions and transformation of ﬁbroblasts
appeared to be involved in Smad pathway. Therefore, the effect
of c-GCE on TGF-b1-induced CTGF, collagen type1, ﬁbronectin
and a-SMA expression was studied. A real-time PCR analysis dem-
onstrated that TGF-b potently enhanced the mRNA expressions of
CTGF, Collagen type1, ﬁbronectin and a-SMA in HFL-1 (Fig. 4A, C,
D and E) or BSMC (Fig. 4B). However, the pretreatment of c-GCE
signiﬁcantly suppressed TGF-b1-induced CTGF mRNA expression
in HFL-1 cells (Fig. 4A) and BSMC (Fig. 4B). Furthermore, in HFL-1
cells, c-GCE markedly and signiﬁcantly suppressed TGF-b1-in-
duced mRNA expressions of collagen type1 (Fig. 4C), ﬁbronectin
(Fig. 4D) and a-SMA (Fig. 4E). These results indicate that the in-
crease in the intracellular GSH level by c-GCE markedly suppressed
the expressions of TGF-b-induced CTGF, collagen type1, ﬁbronectin
and a-SMA through the inhibition of Smad3 activation. CTGF has
been reported to induce collagen type1 and ﬁbronectin in a num-
ber of cell types, and it probably mediates some of the TGF-b-in-
duced ECM production in human cells [6]. We also consideredexpression. HFL-1 cells (A, C, D and E) and BSMC (B) were treated with or without c-
E). Total RNA was extracted and the mRNA expression of CTGF (A and B), collagen
e results are expressed as ratio (%) of the control value. The controls were TGF-b1
nd E) or four (B) experiments. *P < 0.05 compared with control cells.
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ﬁbronectin in the context of the inhibition of CTGF expression.
These ﬁndings in the present study suggest that the glutathione re-
dox status has the potential to regulate TGF-b-induced ﬁbrogenic
effects through its action on ﬁbroblasts and smooth muscle cells.
3.5. All results, including the Smad3 phosphorylation, CTGF expression,
collagen type1 expression, ﬁbronectin expression, a-SMA expression,
were not suppressed by DEX
Corticosteroids are often used systemically for the treatment of
ﬁbrotic lung diseases and severe asthma. DEX is frequently used toFig. 5. Effect of DEX on TGF-b1-induced Smad3 activation, and CTGF, collagen type1, ﬁbr
(10 lM) for 1 h or with c-GCE for 4 h prior to TGF-b1 stimulation for 40 min. The phosph
HFL-1 cells (C, E, F and G) and BSMC (D) were treated with DEX (10 lM) for 1 h or with c
Thereafter, the total RNA was extracted to determine the mRNA expression of CTGF (C an
Values represent means ± S.E.M. of seven (C), six (D, E and G) or ﬁve (F) experiments. *Pevaluate the effect of corticosteroids in vitro. The anti-inﬂamma-
tory effects of corticosteroids have been described in many reports.
We ascertained the marked inhibitory effect of pretreatment with
10 lM DEX on tumor necrosis factor-a induced regulated-on-acti-
vation, normal T-cell-expressed and-secreted chemokine (RANTES)
secretion in BSMC as previously reported (data not shown) [23]. On
the other hand, pretreatment with 10 lMDEX did not change TGF-
b-induced Smad3 phosphorylation in HFL-1 cells (Fig. 5A) and in
BSMC (Fig. 5B) in contrast to the strong inhibitory effect of c-
GCE on Smad3 phosphorylation activated by TGF-b1. Moreover,
DEX enhanced TGF-b1-induced CTGF mRNA expression in HFL-1
cells and BSMC (Fig. 5C and D), and a signiﬁcant difference wasonectin and a-SMA expression. HFL-1 cells (A) and BSMC (B) were treated with DEX
orylated forms of Smad3 and total Smad3 were determined using Western blotting.
-GCE for 4 h prior to TGF-b1 stimulation for 8 h (C) or 12 h (D) or 24 h (E, F and G).
d D), collagen type1 (E), ﬁbronectin (F) or a-SMA (G) using a real-time PCR analysis.
< 0.05 compared with TGF-b1-stimulated cells untreated with c-GCE or DEX.
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cells (Fig. 5C). In addition, DEX did not affect TGF-b1-induced the
mRNA expressions of collagen type1 (Fig. 5E), ﬁbronectin
(Fig. 5F), and a-SMA (Fig. 5G) in HFL-1 cells. In contrast, c-GCE
did suppress the expressions of CTGF, collagen type1, ﬁbronectin,
and a-SMA mRNA (Fig. 5C–G) as the result of Fig. 4. Some reports
have shown that corticosteroid treatment either does not inhibit
ECM deposition [24] or it appears to accelerate ECM deposition
[25]. In addition, corticosteroids have been reported to not sup-
press either the thickening of the airway smooth muscle layer or
subepithelial collagen deposition in an asthma model mouse
[26], thus suggesting our results to be compatible with those ﬁnd-
ings. These ﬁndings indicated that ﬁbrotic changes by TGF-b1 are
resistant to corticosteroid treatment, while these are notably sup-
pressed by c-GCE.
Glutathione is the most prevalent cellular thiol and consists of
reduced glutathione (GSH) and oxidized glutathione (GSSG). The
relative levels of GSH and GSSG inﬂuence the redox status and
are regulated by the redox reaction, the oxidation of the thiol group
and the reduction of the disulﬁde bond [15]. Glutathione is able to
regulate various cellular functions by facilitating reversible con-
structive changes of target proteins or enzymes through the redox
reaction [27,28], that is by ‘‘redox regulation” [28]. In fact, GSH,
which is a major reductant of cellular protein disulﬁdes, can regu-
late the activity of redox-sensitive enzymes by reducing a wide
variety of disulﬁdes [29]. Therefore, it is possible that Smad3 or
other upstream molecules might constructively change under high
intracellular GSH levels, therefore suppressing the activation of
Smad3 by TGF-b. However, further study is required to clarify
the speciﬁc mechanisms that are involved.
In conclusion, we herein demonstrated that glutathione redox is
involved in TGF-b-induced ﬁbrogenic effects, such as CTGF, colla-
gen type1, and ﬁbronectin expression and the transformation of
ﬁbroblasts into myoﬁbroblasts, during the mediation of Smad3
activation. This is the ﬁrst report to describe that glutathione redox
may potentially be able to regulate TGF-b-induced ﬁbroprolifera-
tive effects. This study suggests that glutathione redox could con-
trol TGF-b-induced pathologic ﬁbrosis in the human pulmonary
interstitium and airway.
Acknowledgements
The authors thank Yoko Koike (Department of Medicine and
Molecular Science, Gunma University Graduate School of Medicine)
for the much valuable discussion and Hiroyuki Mochizuki (Depart-
ment of Pediatrics and developmental Medicine, Gunma University
Graduate School of Medicine) for the technical support. This work
was supported in part by Grant 19790680 (to M.U.) from the Min-
istry of Education, Culture, Sport, Science and Technology, Japan.
References
[1] Blobe, G.C., Schiemann, W.P. and Lodish, H.F. (2000) Role of transforming
growth factor beta in human disease. N. Engl. J. Med. 342, 1350–1358.
[2] Bartram, U. and Speer, C.P. (2004) The role of transforming growth factor beta
in lung development and disease. Chest 125, 754–765.
[3] Makinde, T., Murphy, R.F. and Agrawal, D.K. (2007) The regulatory role of TGF-
beta in airway remodeling in asthma. Immunol. Cell Biol. 85, 348–356.
[4] Igarashi, A., Okochi, H., Bradham, D.M. and Grotendorst, G.R. (1993) Regulation
of connective tissue growth factor gene expression in human skin ﬁbroblasts
and during wound repair. Mol. Biol. Cell 4, 637–645.
[5] Leask, A. and Abraham, D.J. (2004) TGF-beta signaling and the ﬁbrotic
response. FASEB J. 18, 816–827.[6] Johnson, P.R., Burgess, J.K., Ge, Q., Poniris, M., Boustany, S., Twigg, S.M. and
Black, J.L. (2006) Connective tissue growth factor induces extracellular matrix
in asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 173, 32–41.
[7] Desmouliere, A., Geinoz, A., Gabbiani, F. and Gabbiani, G. (1993) Transforming
growth factor-beta 1 induces alpha-smooth muscle actin expression in
granulation tissue myoﬁbroblasts and in quiescent and growing cultured
ﬁbroblasts. J. Cell Biol. 122, 103–111.
[8] Burgess, J.K. (2005) Connective tissue growth factor: a role in airway
remodelling in asthma? Clin. Exp. Pharmacol. Physiol. 32, 988–994.
[9] Heldin, C.H., Miyazono, K. and ten Dijke, P. (1997) TGF-beta signalling from
cell membrane to nucleus through SMAD proteins. Nature 390, 465–471.
[10] Flanders, K.C. (2004) Smad3 as a mediator of the ﬁbrotic response. Int. J. Exp.
Pathol. 85, 47–64.
[11] Bonniaud, P., Kolb, M., Galt, T., Robertson, J., Robbins, C., Stampﬂi, M., Lavery,
C., Margetts, P.J., Roberts, A.B. and Gauldie, J. (2004) Smad3 null mice develop
airspace enlargement and are resistant to TGF-beta-mediated pulmonary
ﬁbrosis. J. Immunol. 173, 2099–2108.
[12] Gu, L., Zhu, Y.J., Yang, X., Guo, Z.J., Xu, W.B. and Tian, X.L. (2007) Effect of TGF-
beta/Smad signaling pathway on lung myoﬁbroblast differentiation. Acta
Pharmacol. Sin. 28, 382–391.
[13] Le, A.V., Cho, J.Y., Miller, M., McElwain, S., Golgotiu, K. and Broide, D.H. (2007)
Inhibition of allergen-induced airway remodeling in Smad 3-deﬁcient mice. J.
Immunol. 178, 7310–7316.
[14] Leask, A., Holmes, A., Black, C.M. and Abraham, D.J. (2003) Connective tissue
growth factor gene regulation. Requirements for its induction by transforming
growth factor-beta 2 in ﬁbroblasts. J. Biol. Chem. 278, 13008–13015.
[15] Deneke, S.M. and Fanburg, B.L. (1989) Regulation of cellular glutathione. Am. J.
Physiol. 257, L163–L173.
[16] Utsugi, M., Dobashi, K., Koga, Y., Shimizu, Y., Ishizuka, T., Iizuka, K., Hamuro, J.,
Nakazawa, T. and Mori, M. (2002) Glutathione redox regulates
lipopolysaccharide-induced IL-12 production through p38 mitogen-activated
protein kinase activation in human monocytes: role of glutathione redox in
IFN-gamma priming of IL-12 production. J. Leukoc. Biol. 71, 339–347.
[17] Murata, Y., Shimamura, T. and Hamuro, J. (2002) The polarization of T(h)1/
T(h)2 balance is dependent on the intracellular thiol redox status of
macrophages due to the distinctive cytokine production. Int. Immunol. 14,
201–212.
[18] Utsugi, M., Dobashi, K., Ishizuka, T., Masubuchi, K., Shimizu, Y., Nakazawa, T.
and Mori, M. (2003) C-Jun-NH2-terminal kinase mediates expression of
connective tissue growth factor induced by transforming growth factor-beta1
in human lung ﬁbroblasts. Am. J. Respir. Cell Mol. Biol. 28, 754–761.
[19] Kawata, T., Ishizuka, T., Tomura, H., Hisada, T., Dobashi, K., Tsukagoshi, H.,
Ishiwara, M., Kurose, H., Mori, M. and Okajima, F. (2005) Sphingosine 1-
phosphate inhibits migration and RANTES production in human bronchial
smooth muscle cells. Biochem. Biophys. Res. Commun. 331, 640–647.
[20] Shimizu, Y., Dobashi, K., Iizuka, K., Horie, T., Suzuki, K., Tukagoshi, H.,
Nakazawa, T., Nakazato, Y. and Mori, M. (2001) Contribution of small
GTPase Rho and its target protein rock in a murine model of lung ﬁbrosis.
Am. J. Respir. Crit. Care Med. 163, 210–217.
[21] Ohtsu, A., Kitahara, S. and Fujii, K. (1991) Anticataractogenic property of
gamma-glutamylcysteine ethyl ester in an animal model of cataract. Ophthal.
Res. 23, 51–58.
[22] Vayalil, P.K., Iles, K.E., Choi, J., Yi, A.K., Postlethwait, E.M. and Liu, R.M. (2007)
Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38
and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter.
Am. J. Physiol. Lung Cell Mol. Physiol. 293, L1281–L1292.
[23] Ammit, A.J., Lazaar, A.L., Irani, C., O’Neill, G.M., Gordon, N.D., Amrani, Y., Penn,
R.B. and Panettieri Jr., R.A. (2002) Tumor necrosis factor-alpha-induced
secretion of RANTES and interleukin-6 from human airway smooth muscle
cells: modulation by glucocorticoids and beta-agonists. Am. J. Respir. Cell Mol.
Biol. 26, 465–474.
[24] Pascual, R.M. and Peters, S.P. (2005) Airway remodeling contributes to the
progressive loss of lung function in asthma: an overview. J. Allergy Clin.
Immunol. 116, 477–486.
[25] Johnson, P.R., Black, J.L., Carlin, S., Ge, Q. and Underwood, P.A. (2000) The
production of extracellular matrix proteins by human passively sensitized
airway smooth-muscle cells in culture: the effect of beclomethasone. Am. J.
Respir. Crit. Care Med. 162, 2145–2151.
[26] Henderson Jr., W.R., Chiang, G.K., Tien, Y.T. and Chi, E.Y. (2006) Reversal of
allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J.
Respir. Crit. Care Med. 173, 718–728.
[27] Klatt, P., Molina, E.P., De Lacoba, M.G., Padilla, C.A., Martinez-Galesteo, E.,
Barcena, J.A. and Lamas, S. (1999) Redox regulation of c-Jun DNA binding by
reversible S-glutathiolation. FASEB J. 13, 1481–1490.
[28] Nakamura, H., Nakamura, K. and Yodoi, J. (1997) Redox regulation of cellular
activation. Annu. Rev. Immunol. 15, 351–369.
[29] Ziegler, D.M. (1985) Role of reversible oxidation–reduction of enzyme thiols-
disulﬁdes in metabolic regulation. Annu. Rev. Biochem. 54, 305–329.
